FOLH1 and prostate carcinoma: To evaluate the generalizability of RAiDER, we performed analogous biodistribution assays using a syngeneic murine model of prostate-specific membrane antigen (PSMA)–expressing prostate cancer (RM1.PSMA; Supplemental Fig. 18) by treating tumor-bearing mice with albumin-conjugated caged exatecan and [177Lu]Lu-PSMA-617 (Supplemental Fig. 18) (36).